Cardiotoxicity – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Cardiotoxicity Market Outlook
Thelansis’s “Cardiotoxicity Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Cardiotoxicity treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Cardiotoxicity Overview
Cardiotoxicity
is a comprehensive term that covers a wide range of effects on the heart,
including detectable structural alterations without symptoms, leading to
arrhythmias, increased cardiac biomarkers due to stress and heart injury, and
both systolic and diastolic dysfunction in the left ventricle, even without
signs of heart failure. Cardiotoxicity is a well-recognized complication of
fluoropyrimidines, namely 5-fluorouracil and its oral prodrug capecitabine. The
risk of this adverse effect is heightened in patients undergoing thoracic
radiation therapy simultaneously with multiagent chemotherapy, particularly if
there’s preexisting cardiac disease. The incidence of cardiotoxicity can be as
high as 18% among individuals exposed to fluoropyrimidines. Cardiac toxicity
can present in two forms, reversible or irreversible. Reversibility denotes the
ability to regain cellular or organ function. However, certain myocardial
changes, such as loss of myocardial cells through necrosis or apoptosis, loss
of myofibrils, and deterioration of mitochondria, are generally considered
irreversible in cellular or tissue damage. As per the cardiac review
committee’s assessment, drug-induced cardiotoxicity, specifically
cardiomyopathy, involves one or more of the following criteria: (i) a reduction
in left ventricular ejection fraction (LVEF), either throughout the ventricle
or more prominently in the septum; (ii) indications and symptoms of heart
failure, such as rapid heartbeat and S3 gallop; (iii) a decrease in LVEF that
ranges from equal to or greater than 10% but less than 55%, without
accompanying signs and symptoms of heart failure, or an LVEF decrease from
equal to or less than 5% but less than 55%, combined with signs and symptoms of
heart failure.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment